Xandra Owens Breakefield - Publications

Affiliations: 
Harvard Medical School/ MGH, Boston, MA, United States 
Area:
Neurogenetics, Gene Therapy
Website:
http://www.massgeneral.org/breakefieldlab/

160 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Cheah PS, Prabhakar S, Yellen D, Beauchamp RL, Zhang X, Kasamatsu S, Bronson RT, Thiele EA, Kwiatkowski DJ, Stemmer-Rachamimov A, György B, Ling KH, Kaneki M, Tannous BA, Ramesh V, ... ... Breakefield XO, et al. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances. 7. PMID 33523984 DOI: 10.1126/sciadv.abb1703  0.625
2020 Al Ali J, Vaine CA, Shah S, Campion L, Hakoum A, Supnet ML, Acuña P, Aldykiewicz G, Multhaupt-Buell T, Ganza NGM, Lagarde JBB, De Guzman JK, Go C, Currall B, Trombetta B, ... ... Breakefield XO, et al. TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32975318 DOI: 10.1002/mds.28305  0.592
2020 Cruz L, György B, Cheah PS, Kleinstiver BP, Eimer WA, Garcia SP, Sharma N, Ozelius LJ, Bragg DC, Joung JK, Norberto de Souza O, Macedo Timmers LFS, Breakefield XO. Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. Molecular Therapy. Nucleic Acids. 21: 1-12. PMID 32502938 DOI: 10.1016/J.Omtn.2020.05.009  0.646
2020 Maas SLN, Abels ER, Van De Haar LL, Zhang X, Morsett L, Sil S, Guedes J, Sen P, Prabhakar S, Hickman SE, Lai CP, Ting DT, Breakefield XO, Broekman MLD, El Khoury J. Glioblastoma hijacks microglial gene expression to support tumor growth. Journal of Neuroinflammation. 17: 120. PMID 32299465 DOI: 10.1186/s12974-020-01797-2  0.337
2020 Yekula A, Minciacchi VR, Morello M, Shao H, Park Y, Zhang X, Muralidharan K, Freeman MR, Weissleder R, Lee H, Carter B, Breakefield XO, Di Vizio D, Balaj L. Large and small extracellular vesicles released by glioma cells and . Journal of Extracellular Vesicles. 9: 1689784. PMID 31839905 DOI: 10.1080/20013078.2019.1689784  0.318
2019 Candelario KM, Balaj L, Zheng T, Skog J, Scheffler B, Breakefield X, Schüle B, Steindler DA. Exosome/Microvesicle Content is Altered in LRRK2 Mutant iPSC-derived Neural Cells. The Journal of Comparative Neurology. PMID 31743443 DOI: 10.1002/Cne.24819  0.336
2019 Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, Muller A, Sousa AA, Tsai SQ, Bengtsson NE, Lööv C, Ingelsson M, Chamberlain JS, Corey DP, Aryee MJ, ... ... Breakefield XO, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nature Communications. 10: 4439. PMID 31570731 DOI: 10.1038/S41467-019-12449-2  0.629
2019 Prabhakar S, Cheah PS, Zhang X, Zinter M, Gianatasio M, Hudry E, Bronson RT, Kwiatkowski DJ, Stemmer-Rachamimov A, Maguire CA, Sena-Esteves M, Tannous BA, Breakefield XO. Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy. Methods & Clinical Development. 15: 18-26. PMID 31534984 DOI: 10.1016/J.Ibror.2019.07.1575  0.653
2019 Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, ... ... Breakefield XO, et al. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Reports. 27: 255-268.e6. PMID 30943406 DOI: 10.1016/J.Celrep.2019.03.003  0.317
2018 György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, et al. CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular Therapy. Nucleic Acids. 11: 429-440. PMID 29858078 DOI: 10.1016/J.Omtn.2018.03.007  0.635
2018 Aneichyk T, Hendriks WT, Yadav R, Shin D, Gao D, Vaine CA, Collins RL, Domingo A, Currall B, Stortchevoi A, Multhaupt-Buell T, Penney EB, Cruz L, Dhakal J, Brand H, ... ... Breakefield XO, et al. Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell. 172: 897-909.e21. PMID 29474918 DOI: 10.1016/J.Cell.2018.02.011  0.643
2018 György B, Cruz L, Yellen D, Aufiero M, Alland I, Zhang X, Ericsson M, Fraefel C, Li YC, Takeda S, Hyman BT, Breakefield XO. Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. Scientific Reports. 8: 2324. PMID 29396398 DOI: 10.1038/S41598-018-19865-2  0.341
2018 Reátegui E, van der Vos KE, Lai CP, Zeinali M, Atai NA, Aldikacti B, Floyd FP, H Khankhel A, Thapar V, Hochberg FH, Sequist LV, Nahed BV, S Carter B, Toner M, Balaj L, ... ... Breakefield XO, et al. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications. 9: 175. PMID 29330365 DOI: 10.1038/S41467-017-02261-1  0.31
2017 Bragg DC, Mangkalaphiban K, Vaine CA, Kulkarni NJ, Shin D, Yadav R, Dhakal J, Ton ML, Cheng A, Russo CT, Ang M, Acuña P, Go C, Franceour TN, Multhaupt-Buell T, ... ... Breakefield XO, et al. Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29229810 DOI: 10.1073/Pnas.1712526114  0.634
2017 György B, Sage C, Indzhykulian AA, Scheffer DI, Brisson AR, Tan S, Wu X, Volak A, Mu D, Tamvakologos PI, Li Y, Fitzpatrick Z, Ericsson M, Breakefield XO, Corey DP, et al. Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28082074 DOI: 10.1016/J.Ymthe.2016.12.010  0.652
2016 Zappulli V, Friis KP, Fitzpatrick Z, Maguire CA, Breakefield XO. Extracellular vesicles and intercellular communication within the nervous system. The Journal of Clinical Investigation. 126: 1198-207. PMID 27035811 DOI: 10.1172/Jci81134  0.624
2016 Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO. Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. Cellular and Molecular Neurobiology. PMID 27017608 DOI: 10.1007/S10571-015-0309-0  0.345
2016 Zhang X, Abels ER, Redzic JS, Margulis J, Finkbeiner S, Breakefield XO. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cellular and Molecular Neurobiology. PMID 26951563 DOI: 10.1007/S10571-016-0350-7  0.346
2016 Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. PMID 26905292 DOI: 10.1016/J.Neuropharm.2016.02.013  0.636
2016 Ito N, Hendriks WT, Dhakal J, Vaine CA, Liu C, Shin D, Shin K, Wakabayashi-Ito N, Dy M, Multhaupt-Buell T, Sharma N, Breakefield XO, Bragg DC. Decreased N-TAF1 expression in X-Linked Dystonia-Parkinsonism patient-specific neural stem cells. Disease Models & Mechanisms. PMID 26769797 DOI: 10.1242/Dmm.022590  0.657
2016 Gyorgy B, Ingelsson M, Loov C, Takeda S, Lannfelt L, Hyman BT, Breakefield XO. 567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease Molecular Therapy. 24: S226-S227. DOI: 10.1016/S1525-0016(16)33375-5  0.318
2015 Prabhakar S, Zhang X, Goto J, Han S, Lai C, Bronson R, Sena-Esteves M, Ramesh V, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease. 82: 22-31. PMID 26019056 DOI: 10.1016/J.Nbd.2015.04.018  0.36
2015 Balaj L, Atai NA, Chen W, Mu D, Tannous BA, Breakefield XO, Skog J, Maguire CA. Heparin affinity purification of extracellular vesicles. Scientific Reports. 5: 10266. PMID 25988257 DOI: 10.1038/Srep10266  0.625
2015 Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nature Communications. 6: 7029. PMID 25967391 DOI: 10.1038/Ncomms8029  0.31
2015 Wakabayashi-Ito N, Ajjuri RR, Henderson BW, Doherty OM, Breakefield XO, O'Donnell JM, Ito N. Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in Drosophila melanogaster. Biology Open. 4: 585-95. PMID 25887123 DOI: 10.1242/bio.201411080  0.346
2015 Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, Breakefield XO, Maguire CA, Eichler FS. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 824-34. PMID 25592337 DOI: 10.1038/Mt.2015.6  0.661
2015 Ahmed SG, Hadaegh F, Sena-Esteves M, Maguire CA, Fulci G, Breakefield XO, Brenner GJ. 635. Mechanisms of Caspase-1 Mediated Schwannoma Regression Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34244-7  0.649
2015 Prabhakar S, Zhang X, Goto J, Sena-Esteves M, Ramesh V, Bronson R, Chen JW, Stemmer-Rachamimov AO, Kwiatkowski DJ, Breakefield XO. 196. AAV-Mediated Gene Replacement Therapy in Mouse Model of Tuberous Sclerosis Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33801-1  0.373
2015 Gyorgy B, Sage C, Scheffer D, Indzhykulian AA, Mu D, Breakefield XO, Maguire CA, Corey DP. 16. Exosome-Associated AAV as a Novel Platform for Gene Therapy of Hearing Loss Molecular Therapy. 23: S7. DOI: 10.1016/S1525-0016(16)33620-6  0.649
2014 Rajendran L, Bali J, Barr MM, Court FA, Krämer-Albers EM, Picou F, Raposo G, van der Vos KE, van Niel G, Wang J, Breakefield XO. Emerging roles of extracellular vesicles in the nervous system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15482-9. PMID 25392515 DOI: 10.1523/Jneurosci.3258-14.2014  0.317
2014 Maguire CA, Ramirez SH, Merkel SF, Sena-Esteves M, Breakefield XO. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 817-39. PMID 25159276 DOI: 10.1007/S13311-014-0299-5  0.653
2014 Hettich J, Ryan SD, de Souza ON, Saraiva Macedo Timmers LF, Tsai S, Atai NA, da Hora CC, Zhang X, Kothary R, Snapp E, Ericsson M, Grundmann K, Breakefield XO, Nery FC. Biochemical and cellular analysis of human variants of the DYT1 dystonia protein, TorsinA/TOR1A. Human Mutation. 35: 1101-13. PMID 24930953 DOI: 10.1002/Humu.22602  0.307
2014 Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, Tannous BA, Breakefield XO. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. Acs Nano. 8: 483-94. PMID 24383518 DOI: 10.1021/Nn404945R  0.631
2013 Armata IA, Balaj L, Kuster JK, Zhang X, Tsai S, Armatas AA, Multhaupt-Buell TJ, Soberman R, Breakefield XO, Ichinose H, Sharma N. Dopa-responsive dystonia: functional analysis of single nucleotide substitutions within the 5' untranslated GCH1 region. Plos One. 8: e76975. PMID 24124602 DOI: 10.1371/Journal.Pone.0076975  0.315
2013 Atai NA, Balaj L, van Veen H, Breakefield XO, Jarzyna PA, Van Noorden CJ, Skog J, Maguire CA. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of Neuro-Oncology. 115: 343-51. PMID 24002181 DOI: 10.1007/S11060-013-1235-Y  0.626
2013 Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, ... Breakefield XO, et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Molecular Therapy. Nucleic Acids. 2: e109. PMID 23881452 DOI: 10.1038/Mtna.2013.28  0.623
2013 Prabhakar S, Goto J, Zhang X, Zuang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Stochastic model of Tsc1 lesions in mouse brain. Plos One. 8: e64224. PMID 23696872 DOI: 10.1371/Journal.Pone.0064224  0.329
2013 Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4  0.319
2013 Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Human Gene Therapy. 24: 152-62. PMID 23140466 DOI: 10.1089/Hum.2012.094  0.339
2013 Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 101-8. PMID 22910294 DOI: 10.1038/Mt.2012.161  0.333
2012 Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine. 18: 1835-40. PMID 23142818 DOI: 10.1038/Nm.2994  0.304
2012 Atai NA, Ryan SD, Kothary R, Breakefield XO, Nery FC. Untethering the nuclear envelope and cytoskeleton: biologically distinct dystonias arising from a common cellular dysfunction. International Journal of Cell Biology. 2012: 634214. PMID 22611399 DOI: 10.1155/2012/634214  0.321
2012 Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva-Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M, Breakefield XO, Skog J. Microvesicle-associated AAV vector as a novel gene delivery system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 960-71. PMID 22314290 DOI: 10.1038/Mt.2011.303  0.646
2011 Carter B, Hochberg F, Breakefield X, Balaj L, Sivaraman S, Curry W, Kalkanis SN, Loguidice L, Russo LM, Noerhelm M, Skog J. Use of exosome analysis to reveal glioma-specific genetic changes in patient serum. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2061. PMID 28019922 DOI: 10.1200/Jco.2011.29.15_Suppl.2061  0.333
2011 Wakabayashi-Ito N, Doherty OM, Moriyama H, Breakefield XO, Gusella JF, O'Donnell JM, Ito N. Dtorsin, the Drosophila ortholog of the early-onset dystonia TOR1A (DYT1), plays a novel role in dopamine metabolism. Plos One. 6: e26183. PMID 22022556 DOI: 10.1371/journal.pone.0026183  0.329
2011 Breakefield XO, Frederickson RM, Simpson RJ. Gesicles: Microvesicle "cookies" for transient information transfer between cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1574-6. PMID 21886114 DOI: 10.1038/Mt.2011.169  0.319
2011 van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cellular and Molecular Neurobiology. 31: 949-59. PMID 21553248 DOI: 10.1007/s10571-011-9697-y  0.333
2011 Bragg DC, Armata IA, Nery FC, Breakefield XO, Sharma N. Molecular pathways in dystonia. Neurobiology of Disease. 42: 136-47. PMID 21134457 DOI: 10.1016/J.Nbd.2010.11.015  0.631
2011 Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ. A novel imaging-compatible sciatic nerve schwannoma model. Journal of Neuroscience Methods. 195: 75-7. PMID 21111000 DOI: 10.1016/J.Jneumeth.2010.10.021  0.306
2011 Noerholm M, Bentink S, Strand M, Ter-Ovanesyan D, Lundin E, Ohlson N, Ottander U, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg F, Breakefield X, Carter B, Skog J. Abstract C140: RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C140  0.331
2010 Chen P, Burdette AJ, Porter JC, Ricketts JC, Fox SA, Nery FC, Hewett JW, Berkowitz LA, Breakefield XO, Caldwell KA, Caldwell GA. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Human Molecular Genetics. 19: 3502-15. PMID 20584926 DOI: 10.1093/Hmg/Ddq266  0.304
2010 Cao S, Hewett JW, Yokoi F, Lu J, Buckley AC, Burdette AJ, Chen P, Nery FC, Li Y, Breakefield XO, Caldwell GA, Caldwell KA. Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Disease Models & Mechanisms. 3: 386-96. PMID 20223934 DOI: 10.1242/Dmm.003715  0.335
2010 Prabhakar S, Brenner GJ, Sung B, Messerli SM, Mao J, Sena-Esteves M, Stemmer-Rachamimov A, Tannous B, Breakefield XO. Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Therapy. 17: 266-74. PMID 19834516 DOI: 10.1038/Cgt.2009.71  0.305
2009 Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O, Jacobs AH, García-Añoveros J, Weissleder R, Sena-Esteves M, Corey DP, Breakefield XO. Mutant sodium channel for tumor therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 810-9. PMID 19259066 DOI: 10.1038/Mt.2009.33  0.337
2008 Maguire CA, Meijer DH, LeRoy SG, Tierney LA, Broekman ML, Costa FF, Breakefield XO, Stemmer-Rachamimov A, Sena-Esteves M. Preventing growth of brain tumors by creating a zone of resistance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1695-702. PMID 18714312 DOI: 10.1038/Mt.2008.168  0.643
2008 Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model Journal of Neuroscience. 28: 4406-4413. PMID 18434519 DOI: 10.1523/Jneurosci.0296-08.2008  0.354
2008 Cortés ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraefel C, Breakefield XO. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 81-8. PMID 17998902 DOI: 10.1038/Sj.Mt.6300338  0.371
2007 Hewett JW, Tannous B, Niland BP, Nery FC, Zeng J, Li Y, Breakefield XO. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 7271-6. PMID 17428918 DOI: 10.1073/Pnas.0701185104  0.307
2007 Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Therapy. 14: 460-7. PMID 17304235 DOI: 10.1038/Sj.Cgt.7701037  0.333
2006 Bahn E, Siegert S, Pfander T, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostásy KM. TorsinB expression in the developing human brain. Brain Research. 1116: 112-9. PMID 16938275 DOI: 10.1016/j.brainres.2006.07.102  0.349
2006 Cortés ML, Oehmig A, Perry KF, Sanford JD, Breakefield XO. Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience. 141: 1247-56. PMID 16809004 DOI: 10.1016/j.neuroscience.2006.05.055  0.393
2006 Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods. 3: 391-6. PMID 16628210 DOI: 10.1038/Nmeth875  0.306
2006 McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Research. 66: 2509-13. PMID 16510565 DOI: 10.1158/0008-5472.Can-05-2242  0.321
2006 Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Therapy. 17: 20-30. PMID 16409122 DOI: 10.1089/Hum.2006.17.20  0.349
2006 Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiology of Disease. 22: 98-111. PMID 16361107 DOI: 10.1016/J.Nbd.2005.10.012  0.619
2006 Kock N, Allchorne AJ, Sena-Esteves M, Woolf CJ, Breakefield XO. RNAi blocks DYT1 mutant torsinA inclusions in neurons. Neuroscience Letters. 395: 201-5. PMID 16332410 DOI: 10.1016/j.neulet.2005.10.098  0.323
2006 Messerli S, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Erratum: Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2 (Human Gene Therapy (January 2006) 17, 1 (20-30)) Human Gene Therapy. 17. DOI: 10.1089/Hum.2006.17.796  0.315
2006 Prabhakar S, Messerli S, Rabkin S, Martuza R, Breakefield XO. 151. Treatment of Experimental Schwannomas with HSV Recombinant and Amplicon Vectors Molecular Therapy. 13: S59. DOI: 10.1016/J.Ymthe.2006.08.174  0.359
2006 Tannous BA, Perry KF, Sena-Esteves M, Garcias-Anoveros J, Jacobs A, Corey DP, Weissleder R, Breakefield XO. 959. Tumor Therapy Via Vector-Regulated Expression of Mutant Sodium Channel Molecular Therapy. 13: S370. DOI: 10.1016/J.Ymthe.2006.08.1051  0.343
2005 Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X. Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery Human Gene Therapy. 16: 1367-1376. PMID 16390268 DOI: 10.1089/Hum.2005.16.1367  0.321
2005 Siegert S, Bahn E, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostasy KM. TorsinA expression is detectable in human infants as young as 4 weeks old. Brain Research. Developmental Brain Research. 157: 19-26. PMID 15939081 DOI: 10.1016/j.devbrainres.2005.02.019  0.315
2005 Sharma N, Baxter MG, Petravicz J, Bragg DC, Schienda A, Standaert DG, Breakefield XO. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 5351-5. PMID 15930383 DOI: 10.1523/Jneurosci.0855-05.2005  0.772
2005 Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 435-43. PMID 15727940 DOI: 10.1016/J.Ymthe.2004.10.016  0.359
2005 Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology. 57: 34-41. PMID 15622535 DOI: 10.1002/Ana.20306  0.321
2005 Wang S, Pike L, Petravicz J, Breakefield XO. 164. Bioluminescence Imaging in the CNS after HSV Amplicon Vector Delivery Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.168  0.766
2005 Grandi P, McKee TD, Mok W, Fernandez JL, Breakefield XO, Jain RK. 76. New Strategy To Improve Imaging and Retargeting of HSV-1 Vectors Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.054  0.3
2005 Sharma N, Cristopher Bragg D, Petravicz J, Standaert DG, Breakefield XO. DYT1 transgenic mouse Movement Disorders. 287-292. DOI: 10.1016/B978-012088382-0/50024-4  0.736
2004 Bragg DC, Kaufman CA, Kock N, Breakefield XO. Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA. Molecular and Cellular Neurosciences. 27: 417-26. PMID 15555920 DOI: 10.1016/J.Mcn.2004.07.009  0.619
2004 Hewett JW, Kamm C, Boston H, Beauchamp R, Naismith T, Ozelius L, Hanson PI, Breakefield XO, Ramesh V. TorsinB--perinuclear location and association with torsinA. Journal of Neurochemistry. 89: 1186-94. PMID 15147511 DOI: 10.1111/J.1471-4159.2004.02404.X  0.35
2004 Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Research. 64: 3236-42. PMID 15126365 DOI: 10.1158/0008-5472.Can-03-3516  0.331
2004 Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods (San Diego, Calif.). 33: 179-86. PMID 15121173 DOI: 10.1016/J.Ymeth.2003.11.007  0.349
2004 Bragg DC, Camp SM, Kaufman CA, Wilbur JD, Boston H, Schuback DE, Hanson PI, Sena-Esteves M, Breakefield XO. Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience. 125: 651-61. PMID 15099679 DOI: 10.1016/J.Neuroscience.2004.01.053  0.649
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Breakefield XO, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  0.336
2004 Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO. HSV-1 virions engineered for specific binding to cell surface receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 419-27. PMID 15006609 DOI: 10.1016/J.Ymthe.2003.12.010  0.332
2004 Kamm C, Boston H, Hewett J, Wilbur J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsinA interacts with kinesin light chain 1. The Journal of Biological Chemistry. 279: 19882-92. PMID 14970196 DOI: 10.1074/Jbc.M401332200  0.319
2004 Bragg DC, Slater DJ, Breakefield XO. TorsinA and early-onset torsion dystonia. Advances in Neurology. 94: 87-93. PMID 14509659  0.585
2004 Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Human Gene Therapy. 14: 1247-54. PMID 12952596 DOI: 10.1089/104303403767740786  0.335
2004 Wang S, Petravicz J, Breakefield XO. 64. Bioluminescence Imaging of Regulated Gene Expression Using HSV-1 Amplicon Vectors in Rodent Brain Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.082  0.772
2004 Cole C, Diaz RM, Forshaw M, Kottke T, Thompson J, Gough M, Breakefield X, Sena-Esteves M, Qiao J, Vile RG. 23. T Cell Carriers for Gene Delivery to Tumors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.046  0.346
2003 Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Human Gene Therapy. 14: 1777-85. PMID 14670128 DOI: 10.1089/104303403322611782  0.31
2003 Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 22: 6865-72. PMID 14534533 DOI: 10.1038/Sj.Onc.1206748  0.334
2003 Augood SJ, Keller-McGandy CE, Siriani A, Hewett J, Ramesh V, Sapp E, DiFiglia M, Breakefield XO, Standaert DG. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Research. 986: 12-21. PMID 12965225 DOI: 10.1016/S0006-8993(03)03164-0  0.31
2003 Cortés ML, Bakkenist CJ, Di Maria MV, Kastan MB, Breakefield XO. HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Therapy. 10: 1321-7. PMID 12883528 DOI: 10.1038/Sj.Gt.3301996  0.352
2003 Hampl JA, Camp SM, Mydlarz WK, Hampl M, Ichikawa T, Chiocca EA, Louis DN, Sena-Esteves M, Breakefield XO. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Human Gene Therapy. 14: 611-26. PMID 12804144 DOI: 10.1089/104303403321618137  0.362
2003 Wang S, Petravicz J, Breakefield XO. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 790-800. PMID 12788653 DOI: 10.1016/S1525-0016(03)00094-7  0.777
2003 Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiology of Disease. 12: 11-24. PMID 12609485 DOI: 10.1016/S0969-9961(02)00010-4  0.322
2003 Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L, Nguyen A, Brandt CR, Breakefield XO. HSV-1 amplicon peptide display vector. Journal of Virological Methods. 107: 71-9. PMID 12445940 DOI: 10.1016/S0166-0934(02)00193-3  0.338
2002 Lam P, Hui KM, Wang Y, Allen PD, Louis DN, Yuan CJ, Breakefield XO. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 13: 2147-59. PMID 12542846 DOI: 10.1089/104303402320987842  0.373
2002 Sandler VM, Wang S, Angelo K, Lo HG, Breakefield XO, Clapham DE. Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. Journal of Neuroscience Methods. 121: 211-9. PMID 12468010 DOI: 10.1016/S0165-0270(02)00262-5  0.335
2002 Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (New York, N.Y.). 4: 501-9. PMID 12407444 DOI: 10.1038/Sj.Neo.7900265  0.334
2002 Doheny D, Danisi F, Smith C, Morrison C, Velickovic M, De Leon D, Bressman SB, Leung J, Ozelius L, Klein C, Breakefield XO, Brin MF, Silverman JM. Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology. 59: 1244-6. PMID 12391355 DOI: 10.1212/Wnl.59.8.1244  0.307
2002 Ziefer P, Leung J, Razzano T, Shalish C, LeDoux MS, Lorden JF, Ozelius L, Breakefield XO, Standaert DG, Augood SJ. Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Brain Research. Molecular Brain Research. 101: 132-5. PMID 12007841 DOI: 10.1016/S0169-328X(02)00176-6  0.308
2002 Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Human Gene Therapy. 13: 261-73. PMID 11812282 DOI: 10.1089/10430340252769789  0.35
2001 Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, ... ... Breakefield XO, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 3: 133-43. PMID 11523564 DOI: 10.1007/s100480100111  0.308
2001 Spear MA, Breakefield XO, Beltzer J, Schuback D, Weissleder R, Pardo FS, Ladner R. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Therapy. 8: 506-11. PMID 11498772 DOI: 10.1038/Sj.Cgt.7700334  0.325
2001 Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, Bakowska JC, Breakefield XO, Moskowitz MA. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proceedings of the National Academy of Sciences of the United States of America. 98: 5874-9. PMID 11320217 DOI: 10.1073/pnas.101034998  0.311
2001 Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 591-601. PMID 11319922 DOI: 10.1006/Mthe.2001.0294  0.308
2000 Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy. 7: 1648-55. PMID 11083473 DOI: 10.1038/Sj.Gt.3301272  0.316
2000 Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 347-57. PMID 10933953 DOI: 10.1006/mthe.2000.0046  0.353
2000 Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Annals of Neurology. 48: 65-71. PMID 10894217 DOI: 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L  0.308
2000 Hewett J, Gonzalez-Agosti C, Slater D, Ziefer P, Li S, Bergeron D, Jacoby DJ, Ozelius LJ, Ramesh V, Breakefield XO. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Human Molecular Genetics. 9: 1403-13. PMID 10814722 DOI: 10.1093/Hmg/9.9.1403  0.338
1999 Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, Leung J, Shalish C, Bressman SB, de Leon D, Brin MF, Fahn S, Corey DP, Breakefield XO. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics. 62: 377-84. PMID 10644435 DOI: 10.1006/geno.1999.6039  0.325
1999 Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. Journal of Virology. 73: 10426-39. PMID 10559361 DOI: 10.1128/Jvi.73.12.10426-10439.1999  0.357
1999 Derby ML, Sena-Esteves M, Breakefield XO, Corey DP. Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hearing Research. 134: 1-8. PMID 10452370 DOI: 10.1016/S0378-5955(99)00045-3  0.365
1999 Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh G, Chiocca EA, Breakefield XO. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Therapy. 6: 14-20. PMID 10078959 DOI: 10.1038/Sj.Cgt.7700003  0.354
1998 Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakefield XO. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Therapy. 5: 809-19. PMID 9747461 DOI: 10.1038/Sj.Gt.3300643  0.346
1998 Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Human Gene Therapy. 9: 1261-73. PMID 9650611 DOI: 10.1089/Hum.1998.9.9-1261  0.382
1998 Klein C, Brin MF, de Leon D, Limborska SA, Ivanova-Smolenskaya IA, Bressman SB, Friedman A, Markova ED, Risch NJ, Breakefield XO, Ozelius LJ. De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia. Human Molecular Genetics. 7: 1133-6. PMID 9618171 DOI: 10.1093/hmg/7.7.1133  0.304
1998 Augood SJ, Penney JB, Friberg IK, Breakefield XO, Young AB, Ozelius LJ, Standaert DG. Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Annals of Neurology. 43: 669-73. PMID 9585364 DOI: 10.1002/ana.410430518  0.357
1998 Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO. Targeting gene therapy vectors to CNS malignancies. Journal of Neurovirology. 4: 133-47. PMID 9584951 DOI: 10.3109/13550289809114514  0.348
1998 Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. Journal of the National Cancer Institute. 90: 370-80. PMID 9498487 DOI: 10.1093/Jnci/90.5.370  0.317
1997 Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics. 17: 40-8. PMID 9288096 DOI: 10.1038/ng0997-40  0.317
1997 Ozelius LJ, Hewett J, Kramer P, Bressman SB, Shalish C, de Leon D, Rutter M, Risch N, Brin MF, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, McCormick MK, Fahn S, Buckler AJ, ... ... Breakefield XO, et al. Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium. Genome Research. 7: 483-94. PMID 9149944 DOI: 10.1101/Gr.7.5.483  0.304
1997 Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Human Gene Therapy. 8: 359-70. PMID 9048203 DOI: 10.1089/Hum.1997.8.3-359  0.363
1997 Zimmer C, Wright SC, Engelhardt RT, Johnson GA, Kramm C, Breakefield XO, Weissleder R. Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface. Experimental Neurology. 143: 61-9. PMID 9000446 DOI: 10.1006/Exnr.1996.6350  0.313
1996 Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Human Gene Therapy. 7: 2003-13. PMID 8930661 DOI: 10.1089/Hum.1996.7.16-2003  0.359
1996 Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Human Gene Therapy. 7: 1989-94. PMID 8930659 DOI: 10.1089/Hum.1996.7.16-1989  0.347
1996 Battinelli EM, Boyd Y, Craig IW, Breakefield XO, Chen ZY. Characterization and mapping of the mouse NDP (Norrie disease) locus (Ndp). Mammalian Genome : Official Journal of the International Mammalian Genome Society. 7: 93-7. PMID 8835523 DOI: 10.1007/S003359900026  0.347
1996 Kramm CM, Rainov NG, Sena-Esteves M, Chase M, Pechan PA, Chiocca EA, Breakefield XO. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Human Gene Therapy. 7: 291-300. PMID 8835217 DOI: 10.1089/Hum.1996.7.3-291  0.37
1995 Smith F, Jacoby D, Breakefield XO. Virus vectors for gene delivery to the nervous system. Restorative Neurology and Neuroscience. 8: 21-34. PMID 21551801 DOI: 10.3233/RNN-1995-81207  0.362
1995 Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO. Gene therapy for brain tumors. Brain Pathology (Zurich, Switzerland). 5: 345-81. PMID 8974620 DOI: 10.1111/J.1750-3639.1995.Tb00615.X  0.342
1995 Rainov NG, Zimmer C, Chase M, Kramm CM, Chiocca EA, Weissleder R, Breakefield XO. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Human Gene Therapy. 6: 1543-52. PMID 8664379 DOI: 10.1089/Hum.1995.6.12-1543  0.334
1995 Schuback DE, Chen ZY, Craig IW, Breakefield XO, Sims KB. Mutations in the Norrie disease gene. Human Mutation. 5: 285-92. PMID 7627181 DOI: 10.1002/humu.1380050403  0.302
1995 Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA. Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proceedings of the National Academy of Sciences of the United States of America. 92: 9829-33. PMID 7568227 DOI: 10.1073/Pnas.92.21.9829  0.335
1994 Boviatsis EJ, Chase M, Wei MX, Tamiya T, Hurford RK, Kowall NW, Tepper RI, Breakefield XO, Chiocca EA. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Human Gene Therapy. 5: 183-91. PMID 8186298 DOI: 10.1089/Hum.1994.5.2-183  0.367
1994 Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. The Journal of Comparative Neurology. 339: 3-11. PMID 8106660 DOI: 10.1002/Cne.903390103  0.322
1994 Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TK, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO, Chiocca EA. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Human Gene Therapy. 5: 969-78. PMID 7948146 DOI: 10.1089/Hum.1994.5.8-969  0.346
1994 Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy. 1: 323-31. PMID 7584098  0.613
1993 Chen ZY, Battinelli EM, Hendriks RW, Powell JF, Middleton-Price H, Sims KB, Breakefield XO, Craig IW. Norrie disease gene: characterization of deletions and possible function. Genomics. 16: 533-5. PMID 8314592 DOI: 10.1006/geno.1993.1224  0.359
1993 Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. Rapid-onset dystonia-parkinsonism. Neurology. 43: 2596-602. PMID 8255463 DOI: 10.1212/Wnl.43.12.2596  0.303
1993 Andersen JK, Frim DM, Isacson O, Breakefield XO. Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology. 13: 503-15. PMID 8111822 DOI: 10.1007/Bf00711459  0.36
1993 Frim DM, Short MP, Breakefield XO, Isacson O. Biological Gene-Product Delivery to the Brain: A Protocol for Retroviral Gene Transfer into Cultured Cells and Intracerebral Transplantation Neuroprotocols. 3: 63-68. DOI: 10.1006/Ncmn.1993.1038  0.345
1992 Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research. 33: 493-503. PMID 1335091 DOI: 10.1002/jnr.490330316  0.366
1992 Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Human Gene Therapy. 3: 487-99. PMID 1329993 DOI: 10.1089/hum.1992.3.5-487  0.344
1992 Huang Q, Vonsattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Experimental Neurology. 115: 303-16. PMID 1311266 DOI: 10.1016/0014-4886(92)90196-W  0.333
1992 Sims KB, Lebo RV, Benson G, Shalish C, Schuback D, Chen ZY, Bruns G, Craig IW, Golbus MS, Breakefield XO. The Norrie disease gene maps to a 150 kb region on chromosome Xp11.3. Human Molecular Genetics. 1: 83-9. PMID 1301161 DOI: 10.1093/Hmg/1.2.83  0.32
1991 Chen ZY, Hotamisligil GS, Huang JK, Wen L, Ezzeddine D, Aydin-Muderrisoglu N, Powell JF, Huang RH, Breakefield XO, Craig I. Structure of the human gene for monoamine oxidase type A. Nucleic Acids Research. 19: 4537-41. PMID 1886775 DOI: 10.1093/Nar/19.16.4537  0.321
1991 Cunningham LA, Short MP, Vielkind U, Breakefield XO, Bohn MC. Survival and differentiation within the adult mouse striatum of grafted rat pheochromocytoma cells (PC12) genetically modified to express recombinant beta-NGF. Experimental Neurology. 112: 174-82. PMID 1674694 DOI: 10.1016/0014-4886(91)90067-M  0.315
1990 Diergaarde PJ, Wieringa B, Bleeker-Wagemakers EM, Sims KB, Breakefield XO, Ropers HH. Physical fine-mapping of a deletion spanning the Norrie gene. Human Genetics. 84: 22-6. PMID 2606473 DOI: 10.1007/BF00210665  0.303
1990 Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. Journal of Neuroscience Research. 27: 427-39. PMID 2129047 DOI: 10.1002/Jnr.490270322  0.35
1990 Short MP, Rosenberg MB, Ezzedine ZD, Gage FH, Friedmann T, Breakefield XO. Autocrine differentiation of PC12 cells mediated by retroviral vectors. Developmental Neuroscience. 12: 34-45. PMID 2105198 DOI: 10.1159/000111833  0.324
1989 Shimohama S, Rosenberg MB, Fagan AM, Wolff JA, Short MP, Breakefield XO, Friedmann T, Gage FH. Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene. Brain Research. Molecular Brain Research. 5: 271-8. PMID 2501628 DOI: 10.1016/0169-328X(89)90061-2  0.304
1988 Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO, Gage FH. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science (New York, N.Y.). 242: 1575-8. PMID 3201248 DOI: 10.1126/Science.3201248  0.303
1988 Ozelius L, Hsu YPP, Bruns G, Powell JF, Chen S, Weyler W, Utterback M, Zucker D, Haines J, Trofatter JA, Conneally PM, Gusella JF, Breakefield XO. Human monoamine oxidase gene (MAOA): Chromosome position (Xp21-p11) and DNA polymorphism Genomics. 3: 53-58. PMID 2906043 DOI: 10.1016/0888-7543(88)90159-0  0.302
1987 Seizinger BR, Martuza RL, Rouleau G, Breakefield XO, Gusella JF. Models for inherited susceptibility to cancer in the nervous system: a molecular-genetic approach to neurofibromatosis. Developmental Neuroscience. 9: 144-53. PMID 3119309 DOI: 10.1159/000111618  0.339
1986 Brockes JP, Breakefield XO, Martuza RL. Glial growth factor-like activity in Schwann cell tumors. Annals of Neurology. 20: 317-22. PMID 3767316 DOI: 10.1002/Ana.410200308  0.309
1986 Breakefield XO, Bressman SB, Kramer PL, Ozelius L, Moskowitz C, Tanzi R, Brin MF, Hobbs W, Kaufman D, Tobin A. Linkage analysis in a family with dominantly inherited torsion dystonia: exclusion of the pro-opiomelanocortin and glutamic acid decarboxylase genes and other chromosomal regions using DNA polymorphisms. Journal of Neurogenetics. 3: 159-75. PMID 3016220 DOI: 10.3109/01677068609106846  0.308
1986 Breakefield XO, Stern DF. Oncogenes in neural tumors Trends in Neurosciences. 9: 150-155. DOI: 10.1016/0166-2236(86)90051-2  0.333
1981 Hawkins M, Wallace DC, Eisenstadt JM, Breakefield XO. Expression of monoamine oxidase A and B activities in mouse cybrids and hybrids. Life Sciences. 28: 425-432. PMID 7219055 DOI: 10.1016/0024-3205(81)90089-8  0.325
1974 Breakefield XO, Nirenberg MW. Selection for neuroblastoma cells that synthesize certain transmitters. Proceedings of the National Academy of Sciences of the United States of America. 71: 2530-3. PMID 4152249 DOI: 10.1073/Pnas.71.6.2530  0.539
Show low-probability matches.